Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01283152 · ClinicalTrials.gov registry record · NA

Efficacy Study of Polyethylene Glycol 3350-electrolyte Solution (GoLYTELY®) Versus Lactulose in Patients With Hepatic Encephalopathy.

A NA study, sponsored by University of Texas Southwestern Medical Center.

Completed
Registry status
NA
Development phase
50
Enrollment target

NCT01283152 is a NA study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 50 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01283152, a NA study, has completed, sponsored by University of Texas Southwestern Medical Center.

COMPLETED
Registry status
NA
Development phase
50 participants
Enrollment target

Study Summary

This study is being done to find out if the laxative polyethylene glycol (also known as GoLYTELY® or Miralax®) can treat your hepatic encephalopathy (confusion due to your liver disease and/or cirrhosis) better and/or more safely than lactulose (another laxative). In this study, the investigators will evaluate if polyethylene glycol (GoLYTELY®) is more effective than lactulose on neurocognition (memory and thinking skills) and determine if it decreases the hospital stay.

Interventions

  • DRUG Lactulose
  • DRUG Polyethylene glycol 3350-electrolyte solution (GoLYTELY®)

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2011-01
Est. Completion 2012-06
Phase NA

What the Registry Record Tells You About NCT01283152

The ClinicalTrials.gov registry entry for NCT01283152 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Lactulose is the first listed.

NCT01283152 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01283152 about?

NCT01283152 is a clinical study titled "Efficacy Study of Polyethylene Glycol 3350-electrolyte Solution (GoLYTELY®) Versus Lactulose in Patients With Hepatic Encephalopathy.". This study is being done to find out if the laxative polyethylene glycol (also known as GoLYTELY® or Miralax®) can treat your hepatic encephalopathy (confusion due to your liver disease and/or cirrhosis) better and/or more safely than lactulose (another laxative). In this study, the investigators wi...

What is the current status of trial NCT01283152?

This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2011-01. Estimated completion is 2012-06.

What interventions are being tested in trial NCT01283152?

The interventions under investigation include: Lactulose (DRUG), Polyethylene glycol 3350-electrolyte solution (GoLYTELY®) (DRUG).

Who is sponsoring clinical trial NCT01283152?

This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.